Ying En Biotech-B (09606.HK) achieved an adjusted profit of approximately 1.46 billion yuan in the first half of the year, a year-on-year increase of 14.2%.

Translated to Smart Financial News APP reports that Eune Biotech-B (09606.HK) announced its mid-term performance for 2025, with revenue of approximately 1.29 billion yuan, a year-on-year increase of 22.9%; gross profit of approximately 589 million yuan, a year-on-year increase of 3.73%; research and development expenses of approximately 349 million yuan, a year-on-year decrease of 7.5%; adjusted profit for the period of approximately 146 million yuan, a year-on-year increase of 14.2%.